Evidence map›Paper›PMID 29365086›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2018

Genetic landscape of ultra-stable chronic lymphocytic leukemia patients.

S Raponi, I Del Giudice, M Marinelli, J Wang, L Cafforio, C Ilari, A Piciocchi, M Messina, S Bonina, S Tavolaro and 17 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. The Predominant Prognostic Significance ofCancer management and research · 2021
    Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 10 institutions in 4 countries.

S RaponiHematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
I Del GiudiceHematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
M MarinelliHematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
J WangDivision of Life Science and Department of Chemical and Biological Engineering, Hong Kong University of Science and Technology, Hong Kong.
L CafforioHematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
C IlariHematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
A PiciocchiGIMEMA Data Centre, GIMEMA Foundation, Rome, Italy.
M MessinaHematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
S BoninaHematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
S TavolaroHematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
M BordyuhDepartment of Systems Biology, Columbia University, New York, USA; Department of, Biomedical Informatics, Columbia University, New York, USA.
P MarigliaHematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
N PeragineHematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
F R MauroHematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
S ChiarettiHematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
S MolicaDepartment of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy.
M GentileHematology Uni, Department of Hemato-Oncology, Ospedale Annunziata, Cosenza, Italy.
A VisentinHematology Sectio, Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy.
L TrentinHematology Sectio, Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy.
G M RigolinHematology Sectio, Azienda Ospedaliero Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy.
A CuneoHematology Sectio, Azienda Ospedaliero Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy.
F DiopDivision of Hematolog, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
D RossiDepartment of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Institute of Oncology Research, Bellinzona, Switzerland.
G GaidanoDivision of Hematolog, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
A GuariniDepartment of Molecular Medicine, Sapienza University, Rome, Italy.
R RabadanDepartment of Systems Biology, Columbia University, New York, USA; Department of, Biomedical Informatics, Columbia University, New York, USA.
R FoàHematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy. Electronic address: rfoa@bce.uniroma1.it.
Sapienza University of Rome · ITColumbia University · USUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity of Ferrara · ITUniversity of Padua · ITAzienda Ospedaliera Pugliese Ciaccio · ITFondazione Gimema Onlus · ITHong Kong University of Science and Technology · HKInstitute of Oncology Research · CHOspedale Annunziata di Cosenza · IT

Funding

Clinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2M
Storage System for High Performance ComputingS10OD021764 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2016 to 2016
$600k
NCATS NIH HHS UL1 TR000040NIH HHS S10 OD021764
6 · The paper itself

Abstract

Background: Chronic lymphocytic leukemia (CLL) has a heterogeneous clinical course. Beside patients requiring immediate treatment, others show an initial indolent phase followed by progression and others do not progress for decades. The latter two subgroups usually display mutated IGHV genes and a favorable FISH profile. Patients and methods: Patients with absence of disease progression for over 10 years (10-34) from diagnosis were defined as ultra-stable CLL (US-CLL). Forty US-CLL underwent extensive characterization including whole exome sequencing (WES), ultra-deep sequencing and copy number aberration (CNA) analysis to define their unexplored genetic landscape. Microarray analysis, comparing US-CLL with non-US-CLL with similar immunogenetic features (mutated IGHV/favorable FISH), was also carried out to recognize US-CLL at diagnosis. Results: WES was carried out in 20 US-CLL and 84 non-silent somatic mutations in 78 genes were found. When re-tested in a validation cohort of 20 further US-CLL, no recurrent lesion was identified. No clonal mutations of NOTCH1, BIRC3, SF3B1 and TP53 were found, including ATM and other potential progression driving mutations. CNA analysis identified 31 lesions, none with known poor prognostic impact. No novel recurrent lesion was identified: most cases showed no lesions (38%) or an isolated del(13q) (31%). The expression of 6 genes, selected from a gene expression profile analysis by microarray and quantified by droplet digital PCR on a cohort of 79 CLL (58 US-CLL and 21 non-US-CLL), allowed to build a decision-tree capable of recognizing at diagnosis US-CLL patients. Conclusions: The genetic landscape of US-CLL is characterized by the absence of known unfavorable driver mutations/CNA and of novel recurrent genetic lesions. Among CLL patients with favorable immunogenetics, a decision-tree based on the expression of 6 genes may identify at diagnosis patients who are likely to maintain an indolent disease for decades.

Indexed as

Cohort StudiesDisease ProgressionDNA Copy Number VariationsExome SequencingGenes, p53High-Throughput Nucleotide SequencingHumansImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionIn Situ Hybridization, FluorescenceLeukemia, Lymphocytic, Chronic, B-CellMutationOligonucleotide Array Sequence AnalysisImmunoglobulin Heavy ChainsImmunoglobulin Variable Region

Identifiers

PMID29365086
PMCPMC6248613
OpenAlexW2790775250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.